Prognostic significance of a combination of novel biomarkers in the long-term stratification of adverse outcomes in patients with ST-segment elevation myocardial infarction

A multi-marker approach for assessing the prognosis of patients with ST-segment elevation myocardial infarction (STEMI) is a promising strategy.Aim. To assess the potential prognostic power of soluble growth stimulation gene-2 (sST2), pentraxin 3 (PTX3), and N-terminal pro-brain natriuretic peptide (NT-proBNP) in stratification of the risk of major cardiovascular events (CVE) during 2-year follow-up after STEMI.Material and methods. In 154 patients with STEMI, serum concentrations of NT-proBNP, sST2, and PTx-3 were determined upon admission to hospital. During the two-year follow-up period (734,2±61,2 days), correlation of biomarker concentrations with the risk of a composite endpoint (myocardial infarction + stroke + hospitalization due to cardiovascular disease + cardiovascular death) was analyzed.Results. In the 2-year follow-up, CVE were observed in 81 (55,1%) patients (CV death (n=33; 22,1%), recurrent MI (n=28; 18,.8%), stroke (n=8; 5,4%), hospitalization due to cardiovascular disease other than MI, stroke or cardiovascular death (n=12; 8,2%)). NT-proBNP (HR, 1,19; 95% CI, 1,018-1,32, p